Hering-Smith K, Mao W, Schiro F, Coleman-Barnett J, Pajor A, Hamm L
Urolithiasis. 2014; 42(3):209-19.
PMID: 24652587
PMC: 4106718.
DOI: 10.1007/s00240-014-0653-4.
Kato J, Ruram A, Singh S, Devi S, Devi T, Singh W
Indian J Clin Biochem. 2012; 22(1):128-30.
PMID: 23105666
PMC: 3454268.
DOI: 10.1007/BF02912895.
Goktas C, Horuz R, Akca O, Cetinel C, Canguven O, Kafkasli A
Int Urol Nephrol. 2012; 44(5):1357-62.
PMID: 22581424
DOI: 10.1007/s11255-012-0190-4.
Garcia-Nieto V, Monge-Zamorano M, Gonzalez-Garcia M, Luis-Yanes M
Pediatr Nephrol. 2011; 27(2):261-8.
PMID: 21874585
DOI: 10.1007/s00467-011-1987-6.
Vanachayangkul P, Chow N, Khan S, Butterweck V
Urol Res. 2010; 39(3):189-95.
PMID: 21069311
PMC: 3663934.
DOI: 10.1007/s00240-010-0333-y.
Genetic basis of renal cellular dysfunction and the formation of kidney stones.
Khan S, Canales B
Urol Res. 2009; 37(4):169-80.
PMID: 19517103
PMC: 3625631.
DOI: 10.1007/s00240-009-0201-9.
Can lemon juice be an alternative to potassium citrate in the treatment of urinary calcium stones in patients with hypocitraturia? A prospective randomized study.
Aras B, Kalfazade N, Tugcu V, Kemahli E, Ozbay B, Polat H
Urol Res. 2008; 36(6):313-7.
PMID: 18946667
DOI: 10.1007/s00240-008-0152-6.
Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial.
Allie-Hamdulay S, Rodgers A
Urol Res. 2005; 33(2):116-24.
PMID: 15871014
DOI: 10.1007/s00240-005-0466-6.
Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors.
Costa-Bauza A, Barcelo C, Perello J, Grases F
Int Urol Nephrol. 2003; 34(4):447-51.
PMID: 14577482
DOI: 10.1023/a:1025671019653.
Renal citrate metabolism and urinary citrate excretion in the infant rat.
Melnick J, Preisig P, Alpern R, Baum M
Kidney Int. 2000; 57(3):891-7.
PMID: 10720942
PMC: 4089854.
DOI: 10.1046/j.1523-1755.2000.057003891.x.
Molecular and functional analysis of SDCT2, a novel rat sodium-dependent dicarboxylate transporter.
Chen X, Tsukaguchi H, Chen X, Berger U, Hediger M
J Clin Invest. 1999; 103(8):1159-68.
PMID: 10207168
PMC: 408276.
DOI: 10.1172/JCI5392.
Evolution of lithogenic urinary parameters with a low dose potassium citrate treatment.
Grases F, Conte A, March J
Int Urol Nephrol. 1998; 30(1):1-8.
PMID: 9569103
DOI: 10.1007/BF02550269.
Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation.
Ryall R
World J Urol. 1997; 15(3):155-64.
PMID: 9228722
DOI: 10.1007/BF02201852.
Adenosine triphosphate citrate lyase mediates hypocitraturia in rats.
Melnick J, SRERE P, Elshourbagy N, Moe O, Preisig P, Alpern R
J Clin Invest. 1996; 98(10):2381-7.
PMID: 8941657
PMC: 507690.
DOI: 10.1172/JCI119051.
A new approach to studying inhibitors of calcium oxalate crystal growth.
Hennequin C, Lalanne V, Daudon M, Lacour B, Drueke T
Urol Res. 1993; 21(2):101-8.
PMID: 8389069
DOI: 10.1007/BF01788827.
Hyperoxaluria and renal calculi.
Woolfson R, Mansell M
Postgrad Med J. 1994; 70(828):695-8.
PMID: 7831162
PMC: 2397769.
DOI: 10.1136/pgmj.70.828.695.
Urolithiasis in children: current medical management.
Laufer J, Boichis H
Pediatr Nephrol. 1989; 3(3):317-31.
PMID: 2702115
DOI: 10.1007/BF00858542.
Urolithiasis--historical, comparative and pathophysiological aspects: a review.
Michell A
J R Soc Med. 1989; 82(11):669-72.
PMID: 2687468
PMC: 1292373.
DOI: 10.1177/014107688908201112.
Effects of different doses of alkaline citrate on urine composition and crystallization of calcium oxalate.
Berg C, Larsson L, Tiselius H
Urol Res. 1990; 18(1):13-6.
PMID: 2316066
DOI: 10.1007/BF00294574.
Prophylaxis of uric acid and cystine stones.
Hess B
Urol Res. 1990; 18 Suppl 1:S41-4.
PMID: 2291249
DOI: 10.1007/BF00301527.